CVRx (NASDAQ:CVRX) Price Target Cut to $18.00 by Analysts at Lake Street Capital

CVRx (NASDAQ:CVRX) had its target price cut by Lake Street Capital from $35.00 to $18.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently commented on CVRX. Craig Hallum started coverage on shares of CVRx in a research report on Wednesday. They set a buy rating and a $23.00 target price for the company. Piper Sandler dropped their price objective on CVRx from $33.00 to $15.00 and set an overweight rating for the company in a report on Wednesday. Canaccord Genuity Group reduced their target price on CVRx from $32.00 to $14.00 and set a buy rating on the stock in a report on Wednesday. William Blair lowered CVRx from an outperform rating to a market perform rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. downgraded shares of CVRx from an overweight rating to a neutral rating and cut their price target for the company from $36.00 to $13.00 in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $16.60.

CVRx Stock Up 8.7 %

Shares of NASDAQ:CVRX opened at $9.22 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 14.25 and a quick ratio of 12.86. The stock has a market cap of $199.06 million, a price-to-earnings ratio of -3.76 and a beta of 1.35. The company has a 50 day moving average of $18.11 and a 200-day moving average of $20.90. CVRx has a one year low of $7.77 and a one year high of $33.13.

Insider Buying and Selling at CVRx

In other CVRx news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Paul Verrastro sold 2,545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $21.91, for a total transaction of $55,760.95. Following the sale, the insider now directly owns 2,455 shares in the company, valued at $53,789.05. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 18.30% of the company’s stock.

Institutional Investors Weigh In On CVRx

Several institutional investors have recently bought and sold shares of CVRX. Federated Hermes Inc. bought a new stake in CVRx during the fourth quarter worth $102,000. Valeo Financial Advisors LLC acquired a new position in shares of CVRx during the 1st quarter worth about $346,000. Trexquant Investment LP bought a new stake in shares of CVRx in the 4th quarter valued at about $426,000. Kestra Advisory Services LLC acquired a new stake in CVRx in the 3rd quarter valued at about $462,000. Finally, Jump Financial LLC bought a new position in CVRx during the fourth quarter worth about $499,000. Institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.